Organ transplantation is life-saving but comes with significant risks of complications.
Early (Days to Weeks):
Surgical complications Primary graft dysfunction Acute rejection Infections (bacterial, fungal)
Intermediate (Weeks to Months):
Acute rejection Opportunistic infections (CMV, PCP) Drug toxicity
Late (Months to Years):
Chronic rejection Malignancies Cardiovascular disease Metabolic complications Chronic infections
Major Categories of Complications
Rejection
Hyperacute Rejection:
Occurs within minutes to hours Pre-formed antibodies against donor antigens Rare with modern crossmatching Results in immediate graft loss Treatment: Graft removal, plasmapheresis
Acute Rejection:
Most common in first 6 months Cell-mediated (T-cell) or antibody-mediated (AMR) Incidence: 10-30% depending on organ and immunosuppression
Signs/symptoms vary by organ:
Kidney: rising creatinine, decreased urine output Liver: elevated liver enzymes, jaundice Heart: fatigue, arrhythmias, heart failure Lung: dyspnea, decreased oxygen saturation
Diagnosis:
Biopsy Rising biomarkers (creatinine, liver enzymes Donor-specific antibodies (DSA)
Treatment:
High-dose corticosteroids (pulse methylprednisolone) Thymoglobulin (ATG) for steroid-resistant rejection Plasmapheresis + IVIG for antibody-mediated rejection Rituximab, bortezomib for severe AMR
Chronic Rejection:
Occurs months to years post-transplant Progressive, often irreversible organ dysfunction Manifests differently by organ: Kidney: transplant glomerulopathy, interstitial fibrosis Liver: vanishing bile duct syndrome Heart: cardiac allograft vasculopathy Lung: bronchiolitis obliterans syndrome
Risk factors for post transplant rejection:
Prior acute chronic rejection episodes Non-adherence to immunosuppression Donor-specific antibodies CMV infection HLA mismatches
Management: Optimize immunosuppression May require retransplantation in severe cases
Infections
Transplant recipients are at high risk due to immunosuppression. Bacterial Infections:
Early (first month): Surgical site infections Pneumonia Urinary tract infections Catheter-related bloodstream infections
Later: Encapsulated organisms (especially post-splenectomy) Listeria, Nocardia in heavily immunosuppressed Viral Infections: Cytomegalovirus (CMV): Most common opportunistic infections peak: 1-6 months post-transplant Risk highest in CMV-negative recipient with CMV-positive donor (D+/R-) Manifestations: fever, leukopenia, organ-specific disease (pneumonitis, colitis, hepatitis) Prevention: Valganciclovir prophylaxis 3-6 months Treatment: IV ganciclovir or oral valganciclovir
Epstein-Barr Virus (EBV) Risk for post-transplant lymphoproliferative disorder (PTLD) Monitor EBV PCR levels May require reduction in immunosuppression
BK Virus:Polyoma virus Primarily affects kidney transplants Causes BK nephropathy Monitor BK PCR in urine and blood Treatment: reduction of immunosuppression
Other viruses: Herpes simplex, varicella-zoster (prophylaxis with acyclovir/valacyclovir) COVID-19 (higher morbidity/mortality) Hepatitis B/C reactivation
Fungal Infections:
Common organisms:
Candida (early, often catheter-related) Aspergillus (lung transplant recipients especially) Pneumocystis jirovecii (PCP) Cryptococcus Endemic fungi (histoplasmosis, coccidioidomycosis)
Prevention:
Trimethoprim-sulfamethoxazole for PCP prophylaxis (lifelong) Antifungal prophylaxis in high-risk patients
Parasitic:
Toxoplasmosis, especially heart transplants Strongyloides can cause hyperinfection syndrome
Immunosuppression-Related Complications
Calcineurin Inhibitors (Tacrolimus, Cyclosporine):
Nephrotoxicity
Most significant long-term complication Progressive chronic kidney disease Monitor levels, consider CNI-sparing protocols
Neurotoxicity
Tremor, headaches Posterior reversible encephalopathy syndrome (PRES) Seizures
Metabolic
New-onset diabetes after transplant (NODAT) – 10-40% incidence Hypertension Hyperlipidemia Hyperkalemia, hypomagnesemia
mTOR Inhibitors (Sirolimus, Everolimus):
Delayed wound healing Mouth ulcers Hyperlipidemia Cytopenias (especially thrombocytopenia) Proteinuria Pneumonitis
Mycophenolate:
Gastrointestinal symptoms (diarrhea, nausea) Bone marrow suppression (leukopenia, anemia)
Corticosteroids:
Osteoporosis Avascular necrosis (especially hip) Weight gain, cushingoid features Hyperglycemia Mood changes, insomnia Cataracts, glaucoma
Malignancies
Significantly increased risk (2-4 times general population).
Post-Transplant Lymphoproliferative Disorder (PTLD):
EBV-associated B-cell lymphoma Incidence: 1-20% depending on organ and baseline EBV status Higher risk with heavy immunosuppression, EBV-negative recipients Presentation: lymphadenopathy, organ infiltration, CNS involvement Treatment: reduce immunosuppression, rituximab, chemotherapy
Skin Cancers:
65-fold increased risk of squamous cell carcinoma 10-fold increased risk of basal cell carcinoma Due to UV exposure + immunosuppression Prevention: sun protection, annual dermatology screening Risk increases with mTOR inhibitors less than calcineurin Inhibitors
Other Solid Tumors:
Kidney cancer (native kidneys, especially in ADPKD) Lung cancer Liver cancer Colorectal cancer Kaposi sarcoma (HHV-8 associated)
Cardiovascular Complications Leading cause of late mortality.
Risk factors Pre-existing disease Immunosuppression effects (hypertension, diabetes, hyperlipidemia Chronic inflammation Chronic kidney disease
Manifestations:
Coronary artery disease Heart failure Cardiac allograft vasculopathy (heart transplants) Stroke Peripheral vascular disease
Prevention of post transplant CV complications:
Aggressive cardiovascular risk factor management Statins Blood pressure control Diabetes management Smoking cessation
Metabolic Complications
New-Onset Diabetes After Transplant
Incidence: 10-40% Risk factors: tacrolimus, steroids, obesity, hepatitis C Managed like type 2 diabetes May improve with steroid minimization
Bone Disease: Osteoporosis (steroids, CNIs) Avascular necrosis (steroids)
Prevention: calcium, vitamin D, bisphosphonates
Hyperlipidemia:
Very common (50-70%) Treatment: statins
Obesity: Weight gain common post-transplant Increases cardiovascular and metabolic risks
Kidney Transplant: Ureteral complications (stricture, leak) Renal artery stenosis Lymphocele Recurrent native kidney disease
Liver Transplant: Hepatic artery thrombosis is the most serious vascular complication. Biliary complications of strictures, and leaks Portal vein thrombosis Recurrent hepatitis C or autoimmune disease
Heart Transplant:
Cardiac allograft vasculopathy Right heart failure Pericardial effusion Arrhythmias
Lung Transplant:
Bronchiolitis obliterans syndrome with chronic rejection Airway complications (stenosis, dehiscence) Highest infection risk of all solid organs Primary graft dysfunction
Medication-Related Issues Non-adherence: Major cause of late acute rejection and graft loss Occurs in 20-50% of patients Risk factors: psychiatric illness, substance abuse, cost, complexity of regimen
Drug Interactions:
Many common medications affect immunosuppressant levels CYP3A4 interactions particularly important Grapefruit juice, St. John’s wort contraindicated
Vaccinations:
Complete before transplant when possible Avoid live vaccines post-transplant Annual influenza vaccine Pneumococcal, COVID-19, others per guidelines
Lifestyle:
Sun protection Smoking cessation Healthy diet and exercise Medication adherence
Graft survival varies by organ (approximate 5-year rates)
Kidney: 70-80% Liver: 70-75% Heart: 70-75% Lung: 50-60% (lowest due to chronic rejection)
Patient survival generally
80-90% at 5 years for most solid organs Continues to improve with better immunosuppression and complication management
The key to successful long-term outcomes is balancing adequate immunosuppression to prevent rejection while minimizing infection risk and other complications.